CoChat

Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada

Open access
Quon, Peter, Le, Hoa H., Raymond, Vincent, Mtibaa, Mondher, Moshyk, Andriy · 2016 · Journal of Medical Economics

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Background and objective Venous thromboembolism (VTE) is associated with long-term clinical and economic burden. Clinical guidelines generally recommend at least 3 months of anticoagulation, but, in clinical practice, concerns over bleeding risk often limit extended treatment. Apixaban was studied for extended VTE treatment in the AMPLIFY-EXT trial, demonstrating superiority to placebo in VTE reduction without increasing risk of major bleeding. This study assessed the long-term clinical and economic benefits of extending treatment with apixaban when clinical equipoise exists compared to standard of care with enoxaparin/warfarin and other novel oral anti-coagulants (NOACs) for the treatment and prevention of recurrent VTE in Canada. Methods A Markov model was developed to follow patients with VTE over their lifetimes. Efficacy and safety for apixaban and enoxaparin/warfarin were based on AMPLIFY and AMPLIFY-EXT, while relative efficacy to other NOACs was synthesized by network meta-analysis (NMA). Dosages for NOACs and enoxaparin/warfarin were based on their respective trials and were given up to 18 months and up to 6 months, followed by no treatment, respectively. Patient quality adjusted life years (QALYs) were based on published studies, and costs for resource utilization were from a Ministry of Health perspective, expressed as 2014 CAD ($). Results Extended treatment with apixaban compared to enoxaparin/warfarin resulted in fewer recurrent VTEs, VTE-related deaths, and bleeding events, but at slightly increased cost. The incremental cost-effectiveness ratio was $4828 per QALY gained. Compared to other NOACs, apixaban had the fewest bleeding events, similar recurrent VTE events, and the lowest overall cost, which was driven by the strong bleeding profile. In scenario analyses of acute and lifetime treatments, apixaban was cost-effective against all strategies. Conclusions Extended treatment with apixaban can offer substantial clinical benefits and is a cost-effective alternative to enoxaparin/warfarin and other NOACs.

Overview

Integrity signals

Registry

Crossref · 10.3111/13696998.2016.1141780

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 12

  1. Canadian Agency for Drugs and Technologies in Health., 2013, Antithrombotic agents for the prevention of stroke and systemic embolism in patients with atrial fibrillation
  2. Canadian Agency for Drugs and Technologies in Health (CADTH). common drug review. Canadian Drug Expert Committee (CDEC) Record of Advice: Rivaroxaban (Xarelto–Bayer Inc.) Indication: Deep Vein Thrombosis without Symptomatic Pulmonary Embolism. Ottawa, ON: CADTH, 2013. https://www.cadth.ca/media/cdr/advice_rec/XareltoRFA_RecordofAdvice_April2013%20(with%20redactions).pdf. Accessed February 26, 2014
  3. Canadian Agency for Drugs and Technologies in Health (CADTH). Common drug review. Canadian Drug Expert Committee (CDEC) Final Recommendation: RIVAROXABAN (Xarelto–Bayer Inc.) Ottawa, ON: CADTH, 2013. http://www.cadth.ca/media/cdr/complete/cdr_complete_Xarelto-SPAF-RfA_July-22-13_e.pdf. Accessed February 26, 2014
  4. (OHIP) OMoHaL-TCOHI., 2014, 2014 Schedule of Benefits and Fees
  5. Parent M., 2010, Pharmactuel, 43, 232
  6. Statistics Canada., 2012, Canadian Community Health Survey
  7. Canadian Agency for Drugs and Technologies in Health (CADTH)., 2006, Guidelines for the economic evaluation of health technologies: Canada
  8. Institut national d’excellence en santé et en services sociaux., 2015, ELIQUIS – Traitement des thromboembolies veineuses et prévention des récidives
  9. National Institute for Health and Care Excellence (NICE)., 2015, Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE technology appraisal guidance 341 [TA341]
  10. 10.1001/archinte.1996.00440150083009 · doi:10.1001/archinte.1996.00440150083009 · Paper page
  11. Mittmann N, Seung SJ, Sharma M, et al. Impact of disability status on ischaemic stroke costs (Poster P538). Abstract in Stroke 41;4:e390. 2010 International Stroke Congress. San Antonio, TX; 2010
  12. Statistics Canada., 2014, Consumer Price Index (CPI) for Canada, major components, not seasonally adjusted, historical data. Component: Health and Personal Care. From: Statistics Canada - Catalogue no. 62-001-X. Table 7

Cited by

See all 14

Metadata

Authors
Quon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A.
Affiliations
  • Pfizer (Canada) (CA)
  • Bristol-Myers Squibb (Canada) (CA)
Corresponding author
Quon, Peter
Venue
Journal of Medical Economics
Published
2016-02-03
Volume
19
Issue
6
Pages
557-567
ISSN
  • 1369-6998 (ISSN-L)
  • 1941-837X
OpenAlex
W2262803926
Cited by
12
References
42
Citations by year
2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2017: 5 · 2016: 2
FWCI
3.37
Type
journal article
Language
en
Open access
Locations
  • Journal of Medical Economics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Bristol-Myers Squibb Canada
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
apixaban, long-term anticoagulation, recurrent venous thromboembolism, cost-effectiveness, direct oral anticoagulants, bleeding risk, quality-adjusted life years, Markov model, network meta-analysis
MeSH terms
Anticoagulants, Canada, Cost-Benefit Analysis, Female, Hemorrhage, Humans, Male, Markov Chains, Middle Aged, Pyrazoles, Pyridones, Warfarin, Enoxaparin, Quality-Adjusted Life Years, International Normalized Ratio, Venous Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. https://app.cochat.ai/papers/10.3111/13696998.2016.1141780
The paper
Quon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A. (2016). Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. Journal of Medical Economics. https://doi.org/10.3111/13696998.2016.1141780

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.